Catalyst Pharmaceuticals (CPRX) Getting Somewhat Favorable Media Coverage, Study Shows

Press coverage about Catalyst Pharmaceuticals (NASDAQ:CPRX) has trended somewhat positive this week, according to Accern. The research firm ranks the sentiment of press coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Catalyst Pharmaceuticals earned a media sentiment score of 0.09 on Accern’s scale. Accern also assigned headlines about the biopharmaceutical company an impact score of 46.6063591860623 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.

Here are some of the news headlines that may have impacted Accern Sentiment’s rankings:

Catalyst Pharmaceuticals (CPRX) traded up $0.02 on Friday, hitting $2.93. The stock had a trading volume of 911,539 shares, compared to its average volume of 1,031,026. Catalyst Pharmaceuticals has a fifty-two week low of $1.01 and a fifty-two week high of $3.24.

Several research analysts have weighed in on the company. Zacks Investment Research upgraded Catalyst Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, October 31st. SunTrust Banks, Inc. set a $5.00 price objective on Catalyst Pharmaceuticals and gave the stock a “buy” rating in a report on Tuesday, October 31st. Roth Capital set a $5.00 price objective on Catalyst Pharmaceuticals and gave the stock a “buy” rating in a report on Thursday, August 10th. HC Wainwright reaffirmed a “buy” rating and set a $6.00 price objective on shares of Catalyst Pharmaceuticals in a report on Friday, November 10th. Finally, Piper Jaffray Companies set a $6.00 price objective on Catalyst Pharmaceuticals and gave the stock a “buy” rating in a report on Monday, August 7th. One research analyst has rated the stock with a sell rating and four have given a buy rating to the company. Catalyst Pharmaceuticals presently has a consensus rating of “Buy” and an average price target of $5.50.

TRADEMARK VIOLATION WARNING: “Catalyst Pharmaceuticals (CPRX) Getting Somewhat Favorable Media Coverage, Study Shows” was first published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this article on another website, it was illegally copied and reposted in violation of US & international copyright and trademark law. The original version of this article can be accessed at https://www.dispatchtribunal.com/2017/11/19/catalyst-pharmaceuticals-cprx-getting-somewhat-favorable-media-coverage-study-shows.html.

In other Catalyst Pharmaceuticals news, insider Patrick J. Mcenany purchased 20,000 shares of the stock in a transaction on Tuesday, September 5th. The stock was acquired at an average price of $2.58 per share, with a total value of $51,600.00. Following the completion of the acquisition, the insider now owns 4,471,026 shares in the company, valued at $11,535,247.08. The acquisition was disclosed in a filing with the SEC, which is available at this link. 8.79% of the stock is currently owned by company insiders.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, formerly Catalyst Pharmaceutical Partners, Inc, is a development-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for people with rare debilitating diseases. The Company has three drugs in development: Firdapse, CPP-109 and CPP-115.

Insider Buying and Selling by Quarter for Catalyst Pharmaceuticals (NASDAQ:CPRX)

Receive News & Ratings for Catalyst Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply